Second-trimester maternal serum markers in the prediction of preeclampsia

References

[1] Brown MA, Lindheimer MD, Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Preg. 2001;20:IX–XIV.10.3109/10641950109152635Search in Google Scholar

[2] Pérez-Sepúlveda A, Torres MJ, Valenzuela FJ, Larraín R, Figueroa-Diesel H, Galaz J, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770–5.10.1210/jc.2003-031244Search in Google Scholar PubMed

[3] Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv. 2011;66:225–39.10.1097/OGX.0b013e3182227027Search in Google Scholar PubMed

[4] Sado T, Naruse K, Noguchi T, Haruta S, Yoshida S, Tanase Y, et al. Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res. 2011;60:509–20.10.1007/s00011-011-0319-4Search in Google Scholar PubMed PubMed Central

[5] Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199:122.e1–11.10.1016/j.ajog.2008.01.013Search in Google Scholar PubMed PubMed Central

[6] Lehnen H, Mosblech N, Reineke T, Puchooa A, Menke-Möllers I, Zechner U, et al. Prenatal clinical assessment of sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio as a diagnostic tool for preeclampsia, pregnancy-induced hypertension, and proteinuria. Geburtshilfe Frauenheilkd. 2013;73:440–5.10.1055/s-0032-1328601Search in Google Scholar PubMed PubMed Central

[7] Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346–52.10.1161/HYPERTENSIONAHA.113.01787Search in Google Scholar PubMed

[8] Scazzocchio E, Figueras F, Crispi F, Meler E, Masoller N, Mula R, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol. 2013;208:203.e1–210.10.1016/j.ajog.2012.12.016Search in Google Scholar PubMed

[9] Giguère Y, Charland M, Thériault S, Bujold E, Laroche M, Rousseau F, et al. Linking preeclampsia and cardiovascular disease later in life. Clin Chem Lab Med. 2012;50:985–93.10.1515/cclm.2011.764Search in Google Scholar PubMed

[10] Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy? Arch Gynecol Obstet. 2013;287:865–73.10.1007/s00404-012-2662-2Search in Google Scholar PubMed

[11] Hu D, Tian T, Guo J, Wang H, Chen D, Dong M. Decreased maternal and placental concentrations of follistatin-like 3 in gestational diabetes. Clin Chim Acta. 2012;413:533–6.10.1016/j.cca.2011.10.029Search in Google Scholar PubMed

[12] Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013;208:287.e1–15.10.1016/j.ajog.2013.01.016Search in Google Scholar PubMed PubMed Central

[13] Ree PH, Hahn WB, Chang SW, Jung SH, Kang JH, Cha DH, et al. Early detection of preeclampsia using inhibin a and other second-trimester serum markers. Fetal Diagn Ther. 201;29:280–6.10.1159/000322742Search in Google Scholar PubMed

[14] Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. J Obstet Gynaecol Res. 2013;39:881–90.10.1111/jog.12006Search in Google Scholar PubMed

[15] Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem. 2004;271:1065–78.10.1111/j.1432-1033.2004.04004.xSearch in Google Scholar PubMed

[16] Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. Br J Obstet Gynaecol. 2010;117:1384–89.10.1111/j.1471-0528.2010.02690.xSearch in Google Scholar PubMed

[17] Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. 2004;25:608–22.10.1016/j.placenta.2003.12.009Search in Google Scholar PubMed

[18] Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27:13–7.10.1002/uog.2686Search in Google Scholar PubMed

[19] Guibourdenche J, Frendo JL, Pidoux G, Bertin G, Luton D, Muller F, et al. Expression of pregnancy-associated plasma protein-A (PAPP-A) during human villous trophoblast differentiation in vitro. Placenta. 2003;24:532–9.10.1053/plac.2002.0944Search in Google Scholar PubMed

[20] Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC. Role of the IGF system in trophoblast invasion and preeclampsia. Hum Reprod. 1999;14:90–6.10.1093/humrep/14.suppl_2.90Search in Google Scholar PubMed

[21] Hughes G, Bischof P, Wilson G, Smith R, Klopper A. Assay of placental protein to determine fetal risk. Br Med J. 1980;280:671–3.10.1136/bmj.280.6215.671Search in Google Scholar PubMed PubMed Central

[22] Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87:1762–7.10.1210/jcem.87.4.8430Search in Google Scholar PubMed

[23] Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004;83:37–45.10.1111/j.1600-0412.2004.00277.xSearch in Google Scholar PubMed

[24] Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A,activin A and soluble E-selectin. Hypertens Preg. 2003;22:45–55.10.1081/PRG-120016794Search in Google Scholar PubMed

[25] Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993;150:1804–12.10.4049/jimmunol.150.5.1804Search in Google Scholar PubMed

[26] Rovere-Querini P, Antonacci S, Dell’Antonio G, Angeli A, Almirante G, Cin ED, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148–55.10.1097/01.AOG.0000224607.46622.bcSearch in Google Scholar PubMed

[27] Al-Ramadi BK, Ellis M, Pasqualini F, Mantovani A. Selective induction of pentraxin 3, a soluble innate immune pattern recognition receptor, in infectious episodes in patients with haematological malignancy. Clin Immunol. 2004;112:221–4.10.1016/j.clim.2004.03.012Search in Google Scholar PubMed

[28] Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition and female fertility. Annu Rev Immunol. 2005;23:337–66.10.1146/annurev.immunol.23.021704.115756Search in Google Scholar PubMed

[29] Sado T, Naruse K, Noguchi T, Haruta S, Yoshida S, Tanase Y, et al. Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res. 2011;60:509–20.10.1007/s00011-011-0319-4Search in Google Scholar PubMed PubMed Central

[30] Rovere-Querini P, Antonacci S, Dell’Antonio G, Angeli A, Almirante G, Cin ED, et al. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148–55.10.1097/01.AOG.0000224607.46622.bcSearch in Google Scholar

[31] Larsson A, Palm M, Helmersson J, Axelsson O. Pentraxin 3 values during normal pregnancy. Inflammation. 2011;34:448–52.10.1007/s10753-010-9252-xSearch in Google Scholar PubMed

[32] Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaides KH. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:934–8.10.1002/pd.2311Search in Google Scholar PubMed

[33] Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006;194:1347–53.10.1016/j.ajog.2005.11.018Search in Google Scholar PubMed

[34] Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16:5–15.10.1055/s-2007-1016248Search in Google Scholar PubMed

[35] Cohen A, Lim KH, Lee Y, Rana S, Karumanchi SA, Brown F. Circulating levels of the antiangiogenic marker soluble FMS like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007;30:375–7.10.2337/dc06-1514Search in Google Scholar PubMed

[36] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.10.1056/NEJMoa031884Search in Google Scholar PubMed

[37] Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand. 2010;89:143–6.10.3109/00016340903289892Search in Google Scholar PubMed

[38] Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Acta Obstet Gynecol Scand. 2010;89:143–6.10.3109/00016340903289892Search in Google Scholar PubMed

[39] Peiris HN, Ponnampalam AP, Osepchook CC, Mitchell MD, Green MP. Placental expression of myostatin and follistatin-like-3 protein in a model of developmental programming. Am J Physiol Endocrinol Metab. 2010;298:E854–61.10.1152/ajpendo.00673.2009Search in Google Scholar PubMed

[40] Zheng YL, Ma HM, Zheng YM, Wang YS, Zhang BW, He XY, et al. Site-directed mutagenesis of the myostatin gene in ovine fetal myoblast cells in vitro. Res Vet Sci. 2012;93:763–9.10.1016/j.rvsc.2011.10.022Search in Google Scholar PubMed

[41] Mitchell MD, Osepchook CC, Leung KC, McMahon CD, Bass JJ. Myostatin is a human placental product that regulates glucose uptake. J Clin Endocrinol Metab. 2006;91:1434–7.10.1210/jc.2005-2361Search in Google Scholar PubMed

[42] Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147:3586–97.10.1210/en.2006-0089Search in Google Scholar PubMed

[43] Peiris HN, Lappas M, Georgiou HM, Vaswani K, Salomon C, Rice GE, et al. Myostatin in the placentae of pregnancies complicated with gestational diabetes mellitus. Placenta. 2015;36:1–6.10.1016/j.placenta.2014.11.006Search in Google Scholar PubMed

[44] Robertson RD, Mukherjee A. Synexpression group analyses identify new functions of FSTL3, a TGFβ ligand inhibitor. Biochem Biophys Res Commun. 2012;427:568–73.10.1016/j.bbrc.2012.09.098Search in Google Scholar PubMed

[45] Okamoto A, Endo H, Kalionis B, Shinya M, Saito M, Nikaido T, et al. IGFBP1 and follistatin-like 3 genes are significantly up-regulated in expression profiles of the IUGR placenta. Placenta. 2006;27:317–21.10.1016/j.placenta.2004.12.007Search in Google Scholar PubMed

[46] Biron-Shental T, Schaiff WT, Rimon E, Shim TL, Nelson DM, Sadovsky Y. Hypoxia enhances the expression of follistatin-like 3 in term human trophoblasts. Placenta. 2008;29:51–7.10.1016/j.placenta.2007.09.001Search in Google Scholar PubMed PubMed Central

[47] Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004;11:342–52.10.1016/j.jsgi.2004.03.003Search in Google Scholar PubMed